SCHEMBL339676

SCHEMBL339676

CCCCCCCCCCCCCCCC=C1CCC(OC(C)OP(=O)(O)OCC[N+](C)(C)C)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
S1PR1 P21453 1/20 0.37
LMNA P02545 2/20 0.37
AKT1 P31749 2/20 0.37
ESR1 P03372 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
CDC25A P30304 1/20 0.37
AGTR1 P30556 1/20 0.37
ADRA1A P35348 1/20 0.37
KCNH2 Q12809 1/20 0.37
ALDH1A1 P00352 2/20 0.35
PRKD3 O94806 1/20 0.35
PRKCG P05129 1/20 0.35
PRKCB P05771 1/20 0.35
PRKCA P17252 1/20 0.35
PRKCH P24723 1/20 0.35
PRKCI P41743 1/20 0.35
PRKCE Q02156 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL339430 1.00 FABP3 (0.38) FABP3MEN1KMT2AS1PR1LMNA
SCHEMBL339696 1.00 FABP3 (0.38) FABP3MEN1KMT2AS1PR1LMNA
SCHEMBL5673069 0.83 FABP3 (0.41) FABP3MEN1KMT2AS1PR1LMNA
SCHEMBL340042 0.83 CDC25A (0.34) AKT1CDC25ALPAR3
SCHEMBL338951 0.83 CDC25A (0.34) AKT1CDC25ALPAR3
SCHEMBL339932 0.83 CDC25A (0.34) AKT1CDC25ALPAR3
SCHEMBL339733 0.82
SCHEMBL338888 0.81 FABP3 (0.41) FABP3MEN1KMT2ALMNAAKT1
SCHEMBL339774 0.81 FABP3 (0.41) FABP3MEN1KMT2ALMNAAKT1
SCHEMBL5663655 0.74 LPAR3 (0.36) S1PR1LPAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097752-B2 Antiprotozoal ring-substituted phospholipids MAKSCIENTIFIC, LLC (US) 2012-01-17 US claimed
US-8097752-B2 Antiprotozoal ring-substituted phospholipids MAKSCIENTIFIC, LLC (US) 2012-01-17 US disclosed
US-20060105998-A1 Antiprotozoal ring-substiuted phospholipids MAK SCIENTIFIC CORPORATION (US) 2006-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060105998-A1 Antiprotozoal ring-substiuted phospholipids PHOSPHO1, PLTP, PLA2G2C FABP3 3547/4885MEN1 2778/4885KMT2A 3728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.